A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...
The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...
One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service.Most Read from BloombergHow the 2025 ...
The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.
However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...
There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback